WHAT IS CLAIMED IS:

1. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21-day docetaxel treatment cycle, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.

2. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose in a 21-day docetaxel treatment cycle less than 2 hours after the administration of docetaxel, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.

3. The use of claim 1 or 2, wherein the amount of plinabulin in the single dose is greater than 1 mg/m2 and less than 40 mg/m2.

4. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose in a 21-day docetaxel treatment cycle less than 20 mg/m2, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.

5. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of docetaxel-induced neutropenia, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21-day docetaxel treatment cycle, wherein the amount of plinabulin to be administered is less than 30 mg/m2 per treatment cycle, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.

6. The use of any one of claims 1 to 5, wherein the plinabulin is to be administered less than 1 hour after the administration of docetaxel.

7. The use of any one of claims 1 to 5, wherein the plinabulin is to be administered about 30 mins after the administration of docetaxel.

8. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in combination with one or more G-CSF drug for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide

(TC) chemotherapy-induced neutropenia induced by a chemotherapy regimen comprising at least one of docetaxel or cyclophosphamide, wherein the plinabulin is to be administered as a single dose in a 21-day treatment cycle, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.

9. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) or Docetaxel and Cyclophosphamide (TC) chemotherapy-induced neutropenia induced by a chemotherapy regimen comprising at least one of docetaxel or cyclophosphamide, wherein the plinabulin is to be administered as a single dose of plinabulin in a 21- day treatment cycle, wherein the amount of plinabulin to be administered is less than 30 mg/m2 per treatment cycle, and wherein G-CSF is to be administered at a dose in the range of 3 mg to 6 mg.